TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of “Buy” from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) have earned an average recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $32.17.

Several equities analysts have recently weighed in on the stock. Morgan Stanley decreased their price target on shares of TransMedics Group from $22.00 to $15.00 and set an “equal weight” rating for the company in a research note on Friday, February 25th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, March 17th. JPMorgan Chase & Co. decreased their price target on shares of TransMedics Group from $20.00 to $12.00 in a research note on Thursday, February 24th. Zacks Investment Research raised shares of TransMedics Group from a “sell” rating to a “hold” rating in a research note on Tuesday, March 1st. Finally, Canaccord Genuity Group raised their price target on shares of TransMedics Group from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, March 17th.

NASDAQ TMDX opened at $21.34 on Monday. The business’s 50 day simple moving average is $21.25. TransMedics Group has a 52-week low of $10.00 and a 52-week high of $35.37. The company has a current ratio of 5.11, a quick ratio of 4.47 and a debt-to-equity ratio of 0.52. The company has a market cap of $596.71 million, a PE ratio of -13.25 and a beta of 1.72.

TransMedics Group (NASDAQ:TMDXGet Rating) last posted its earnings results on Wednesday, February 23rd. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). TransMedics Group had a negative return on equity of 53.10% and a negative net margin of 146.11%. The business had revenue of $9.67 million for the quarter, compared to the consensus estimate of $7.66 million. During the same period in the previous year, the company posted ($0.23) earnings per share. Analysts anticipate that TransMedics Group will post -1.38 EPS for the current fiscal year.

In other TransMedics Group news, VP John F. Carey sold 4,500 shares of the firm’s stock in a transaction on Monday, March 28th. The stock was sold at an average price of $25.01, for a total transaction of $112,545.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John F. Carey sold 1,500 shares of the firm’s stock in a transaction on Friday, April 1st. The shares were sold at an average price of $26.85, for a total value of $40,275.00. Following the sale, the vice president now directly owns 379 shares of the company’s stock, valued at approximately $10,176.15. The disclosure for this sale can be found here. 10.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc lifted its holdings in shares of TransMedics Group by 154.7% during the fourth quarter. NEXT Financial Group Inc now owns 1,322 shares of the company’s stock worth $25,000 after buying an additional 803 shares in the last quarter. UBS Group AG increased its position in shares of TransMedics Group by 28.7% in the third quarter. UBS Group AG now owns 3,025 shares of the company’s stock worth $100,000 after purchasing an additional 675 shares during the period. Citigroup Inc. grew its position in TransMedics Group by 79.8% in the third quarter. Citigroup Inc. now owns 3,342 shares of the company’s stock valued at $111,000 after acquiring an additional 1,483 shares during the last quarter. Royal Bank of Canada grew its position in TransMedics Group by 148.3% in the second quarter. Royal Bank of Canada now owns 4,318 shares of the company’s stock valued at $144,000 after acquiring an additional 2,579 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of TransMedics Group by 475.0% during the third quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the company’s stock worth $167,000 after purchasing an additional 4,166 shares during the last quarter. 70.79% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile (Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Further Reading

Analyst Recommendations for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.